Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CBAN vs ATLO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATLO Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

ATLO Overall Winner 6-Pillar Tally: CBAN 2 – 4 ATLO Matrix Metrics: CBAN 4 – 6 ATLO

As of Nov 20, 2026, AMES National Corp (ATLO) is the stronger overall head-to-head candidate over Colony Bankcorp Inc. (CBAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CBAN carries a Unified Composite Score of 44.5/100 (HOLD) at $19.22 (8.0x Forward P/E, 33.4% operating margin), whereas ATLO carries 54.4/100 (HOLD) at $32.57 (11.0x Forward P/E, 44.6% operating margin).

  • Technical & Structure Timing Caution: CBAN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile ATLO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 41.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CBAN vs ATLO
CBAN NYSE
Colony Bankcorp Inc.
State Commercial Banks
$19.22
-1.99% 1D
Market Cap $535.3M
TTM Revenue $154M
Forward P/E 8.0x
Beta / 30D Vol 0.39β · 19% Vol
Unified Composite Score
44.5 / 100 HOLD
Tech 30.0 Fund 46.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.4%), weak momentum, RSI 32
RSI-14: 32.4 · SMA20: $20.23 · SMA50: $20.32
ATLO NASDAQ Head-to-Head Winner
AMES National Corp
National Commercial Banks
$32.57
-0.46% 1D
Market Cap $289.8M
TTM Revenue $76M
Forward P/E 11.0x
Beta / 30D Vol 0.22β · 22% Vol
Unified Composite Score
54.4 / 100 HOLD
Tech 61.0 Fund 53.0 Flow 70.0 Mom 26.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.2 · SMA20: $33.79 · SMA50: $32.79

6-Pillar Scorecard Institutional Category Breakdown (CBAN 2 – 4 ATLO)

Columns: Metric · CBAN · ATLO
1. Valuation Multiples CBAN
Forward P/E 8.0x 11.0x
Trailing P/E 10.8x 11.4x
PEG Ratio 2.11x 1.03x
EV / Revenue 3.5x 2.8x
2. Growth & Scale ATLO
Revenue Growth (YoY) +26.0% +27.6%
Earnings Growth (YoY) +50.2% +55.2%
TTM Revenue (USD) $154M $76M
Market Cap $535.3M $289.8M
3. Profitability & Quality ATLO
Gross Margin 100.0% 100.0%
Operating Margin 33.4% 44.6%
Net Profit Margin 24.3% 33.3%
Return on Equity (ROE) 10.8% 12.5%
4. Balance Sheet & Cash Flow ATLO
Cash Generation (TTM) N/A $22M
Cash Flow Margin N/A 29.2%
Net Cash / Leverage $18.46 Book/Sh · 10.8% ROE $78M Net Cash
Dividend Yield 2.39% 2.78%
5. Options & Positioning ATLO
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 594.7% (100th %ile) 39.0% (20th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat CBAN
OpEx & R&D Intensity 66.6% of Rev ($102M) 55.4% of Rev ($42M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Banks - Regional Operator Banks - Regional Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CBAN (4) vs ATLO (6)
Institutional Metric CBAN ATLO Criterion Row Edge
Market Capitalization
Scale
$535.3M $289.8M Larger Scale CBAN
Trailing P/E Ratio
Valuation
10.8x 11.4x Lower Multiple CBAN
Forward P/E Ratio
Valuation
8.0x 11.0x Lower Multiple CBAN
Revenue Growth (YoY)
Growth
+26.0% +27.6% Higher Growth ATLO
Operating Margin (TTM)
Profitability
33.4% 44.6% Higher Margin ATLO
Net Profit Margin
Profitability
24.3% 33.3% Higher Margin ATLO
Return on Equity (ROE)
Capital Efficiency
10.8% 12.5% Higher ROE ATLO
52-Week Range Position
Momentum
49% ($16–$22) 80% ($21–$35) Stronger Trend ATLO
Beta / 30D Volatility
Risk Regime
0.39β · 19% Vol 0.22β · 22% Vol Lower Realized Risk CBAN
Unified Institutional Score
Composite Signal
44.5 / 100 (HOLD) 54.4 / 100 (HOLD) Higher Composite ATLO
Trailing 12M Revenue (USD)
Operating Scale
$154M $76M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
2.11x PEG · 3.5x EV/Rev 1.03x PEG · 2.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($18.46 Book/Sh · 10.8% ROE) $22M ($78M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATLO +0.77 pp
CBAN: -5.09% · ATLO: -4.32%
3M Horizon ATLO +12.36 pp
CBAN: -10.1% · ATLO: +2.26%
6M Horizon ATLO +16.06 pp
CBAN: -2.93% · ATLO: +13.13%
1Y Horizon ATLO +36.53 pp
CBAN: +18.94% · ATLO: +55.47%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CBAN vs ATLO. Trailing 12-month operating profitability (CBAN 33.4% vs ATLO 44.6%) and valuation multiples (CBAN 8.0x vs ATLO 11.0x Forward P/E) are benchmarked directly in Pillar 4 below.

CBAN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$154M
Gross Margin100.0%
Op. Margin33.4%
ROE / Fwd P/E10.8% · 8.0x
ATLO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$76M
Gross Margin100.0%
Op. Margin44.6%
ROE / Fwd P/E12.5% · 11.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CBAN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 594.7%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact CBAN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ATLO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 39.0%
IV Percentile 20th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATLO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CBAN Moat Profile High-Margin Pricing Power Moat
Banks - Regional Operator
Competes within the Banks - Regional value chain with $535.3M market capitalization and 33.4% operating margin.
OpEx & R&D Reinvestment 66.6% of Rev ($102M)
90D Engineering Disclosures 0 Published
ATLO Moat Profile High-Margin Pricing Power Moat
Banks - Regional Operator
Competes within the Banks - Regional value chain with $289.8M market capitalization and 44.6% operating margin.
OpEx & R&D Reinvestment 55.4% of Rev ($42M)
90D Engineering Disclosures 0 Published

Investor FAQ CBAN vs ATLO Key Questions & Quantitative Answers

As of Nov 20, 2026, AMES National Corp (ATLO) is the stronger overall head-to-head candidate over Colony Bankcorp Inc. (CBAN) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). CBAN carries a Unified Composite Score of 44.5/100 (HOLD) at $19.22 (8.0x Forward P/E, 33.4% operating margin), whereas ATLO carries 54.4/100 (HOLD) at $32.57 (11.0x Forward P/E, 44.6% operating margin). Technical & Structure Timing Caution: CBAN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.4); meanwhile ATLO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 41.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ATLO leads the Growth & Scale pillar: CBAN posts +26.0% YoY revenue growth and +50.2% YoY earnings growth on $154M TTM revenue (100.0% gross margin, 33.4% operating margin), compared with ATLO at +27.6% YoY revenue growth and +55.2% YoY earnings growth on $76M TTM revenue (100.0% gross margin, 44.6% operating margin). On trailing 12-month operating scale, CBAN generates $154M in USD-normalized revenue versus $76M for ATLO. In operating R&D and SG&A reinvestment, CBAN deploys 66.6% of Rev ($102M) (0 90-day corporate R&D disclosures) versus 55.4% of Rev ($42M) (0 disclosures) for ATLO.

CBAN screens cheaper on headline valuation multiples. CBAN trades at 8.0x Forward P/E, 10.8x Trailing P/E, 2.11x PEG, and 3.5x EV/Revenue (unreported cash flow margin), whereas ATLO trades at 11.0x Forward P/E, 11.4x Trailing P/E, 1.03x PEG, and 2.8x EV/Revenue (29.2% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CBAN (10.8% ROE) versus ATLO (12.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CBAN carries 594.7% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.39β · 19% Vol realized risk). By comparison, ATLO carries 39.0% implied volatility (20th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.22β · 22% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.